CVS Partners with Eli Lilly for $25 GLP-1 Access, Launching Q4
CVS sits 61% above its 52-week low of $61.35.
Summary
CVS is expanding its weight management platform with Eli Lilly, offering transparent pricing for Zepbound and Foundayo through its app. Eligible commercially insured patients could pay as little as $25 per month, while uninsured may access medications for $149 via vouchers. A $29 virtual MinuteClinic visit enables GLP-1 prescriptions. Same-day pickup at 9,000 CVS locations begins early Q4 2026. This builds on the earlier GLP-1 program revamp announced today, adding concrete pricing and a major pharma partnership. The move positions CVS to capture more of the booming weight-loss drug market, directly competing with telehealth and pharmacy rivals.
At the time of this announcement, CVS was trading at $99.04 on NYSE in the Trade & Services sector, with a market capitalization of approximately $126.4B. The 52-week trading range was $61.35 to $110.68. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.